I. Pellegrin

发表

Covichem: A biochemical severity risk score of COVID-19 upon hospital admission

S. Dabernat, F. Moreau-Gaudry, A. Bedel, 2021, PloS one.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

C. Fagard, Y. Yazdanpanah, B. Spire, 2018, The Journal of antimicrobial chemotherapy.

Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.

H. Fleury, P. Massip, J. Puel, 2000 .

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.

J. Pellegrin, J. Maugein, I. Pellegrin, 1996, The Journal of antimicrobial chemotherapy.

Evaluation of New Quantitative Assays for Diagnosis and Monitoring of Cytomegalovirus Disease in Human Immunodeficiency Virus-Positive Patients

D. Neau, H. Fleury, J. Pellegrin, 1999, Journal of Clinical Microbiology.

Dual Nucleoside Regimens in Nonadvanced HIV Infection: Prospective Follow‐Up of 130 Patients, Aquitaine Cohort, 1996 to 1998

D. Neau, P. Morlat, L. Dequae-Merchadou, 2000, Journal of acquired immune deficiency syndromes.

Fatty acids and plasma antioxidants in HIV-positive patients: correlation with nutritional and immunological status.

C. Sergeant, J. Pellegrin, M. Thomas, 1995, Clinical biochemistry.

Resuming Training in High-Level Athletes After Mild COVID-19 Infection: A Multicenter Prospective Study (ASCCOVID-19)

P. Jaïs, H. Cochet, S. Doutreleau, 2022, Sports Medicine - Open.

HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs.

Huynh Tan Tien, H. Fleury, I. Pellegrin, 2003, AIDS research and human retroviruses.

Serum suppression of tu morigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients

M. Dupon, F. Dabis, Y. Lévy, 2017 .

Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open‐label, multicenter phase 4 trial

N. Kamar, T. Bachelet, R. Thiébaut, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients

B. Liquet, J. Moreau, P. Blanco, 2017, PloS one.

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort.

D. Neau, M. Dupon, F. Dabis, 2013, The Journal of infectious diseases.

Plasma lipids in HIV‐infected patients: a prospective study in 95 patients

C. Sergeant, H. Fleury, J. Pellegrin, 1994, European journal of clinical investigation.

The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study.

E. Lazaro, P. Blanco, P. Duffau, 2020, Joint bone spine.

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

É. Darbo, V. Brouste, G. MacGrogan, 2022, ESMO open.

Change in T lymphocytes count after HAART initiation in HIV-infected patients with history of Mycobacterium avium complex infection

D. Commenges, F. Dabis, J. Moreau, 2008 .

Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of Mycobacterium Avium Complex Infection

D. Commenges, F. Dabis, J. Moreau, 2005, Antiviral therapy.

AVT-974 Lazaro

D. Commenges, F. Dabis, J. Moreau, 2006 .

Serum selenium predicts outcome in HIV infection.

C. Sergeant, H. Fleury, J. Pellegrin, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients.

H. Fleury, D. Ekouevi, G. Chêne, 2000, The Journal of infectious diseases.

Foscarnet decreases HIV-1 plasma load.

D. Breilh, J. Ragnaud, M. Dupon, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma.

M. Dupon, H. Fleury, J. Viallard, 1999, Microvascular research.

JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients.

J. Ragnaud, H. Fleury, J. Pellegrin, 1998, The Journal of infectious diseases.

One-year antioxidant supplementation with beta-carotene or selenium for patients infected with human immunodeficiency virus: a pilot study.

C. Sergeant, H. Fleury, J. Pellegrin, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients

C. Katlama, G. Le Teuff, H. Fleury, 2006, Hepatology.

Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)

J. Durrieu, J. Montastruc, J. Chastang, 2022, Clinical Microbiology and Infection.

Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

Hélène Budzinski, Dominique Breilh, D. Breilh, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.

P. Massip, J. Izopet, M. Segondy, 1999, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Resistance Mutations Affect Virologic Response to Ritonavir/Saquinavir-Containing Regimens

D. Breilh, D. Neau, H. Fleury, 2001, Therapeutic drug monitoring.

Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients

D. Breilh, D. Neau, F. Dabis, 2007, Antimicrobial Agents and Chemotherapy.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Virological Responses to Atazanavir–Ritonavir-Based Regimens: Resistance-Substitutions Score and Pharmacokinetic Parameters (Reyaphar Study)

D. Breilh, D. Neau, J. Ragnaud, 2005, Antiviral therapy.

Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study)

D. Breilh, D. Neau, H. Fleury, 2008, Antiviral therapy.

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study)

D. Breilh, H. Fleury, H. Budzinski, 2004, AIDS.

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2007, Antiviral therapy.

Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV-1 MONITOR 1.0 Assay for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma of Patients Receiving Stavudine-Didanosine Combination Therapy

M. Peeters, C. Pasquier, J. Puel, 1998, Journal of Clinical Microbiology.

Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals

H. Fleury, A. Aubertin, A. Kirn, 1997, Journal of virology.

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2003, AIDS.

Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.

B. Hoen, J. Levy, M. Dalod, 1998, The Journal of infectious diseases.

Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.

D. Neau, J. Ragnaud, M. Dupon, 1997, AIDS research and human retroviruses.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time

C. Rouzioux, L. Meyer, C. Tamalet, 2006, AIDS.

French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002

F. Brun-Vézinet, P. André, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment.

C. Rouzioux, B. Hoen, L. Meyer, 2002, AIDS.

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

H. Fleury, P. Massip, J. Puel, 1999, AIDS.

Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.

R. Salamon, P. Morlat, G. Chêne, 2001, Clinical immunology.

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

J. Ragnaud, M. Dupon, H. Fleury, 2003, The Journal of infectious diseases.

HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.

M. Mouroux, V. Calvez, C. Rouzioux, 2000, AIDS research and human retroviruses.

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters

H. Fleury, J. Moreau, J. Viallard, 2005, Journal of medical virology.

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 106 cells/l

H. Fleury, J. Moreau, J. Viallard, 2005, AIDS.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy

C. Rouzioux, L. Meyer, M. Sinet, 2001, AIDS.

Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA

H. Fleury, B. Hoen, I. Pellegrin, 2000, AIDS.

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients

J. Moreau, E. Lazaro, P. Blanco, 2015, AIDS.

Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

B. Masquelier, D. Neau, J. Ragnaud, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults

E. Lazaro, P. Blanco, P. Duffau, 2018, AIDS.

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2019, BMJ Open.

mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional αβ and γδ T cells in Kidney Transplantation

R. Thiébaut, M. Mamani-Matsuda, J. Déchanet-Merville, 2021, Journal of the American Society of Nephrology : JASN.

Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis.

H. Fleury, A. Caumont, I. Pellegrin, 2001, Journal of virological methods.

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment

D. Neau, F. Dabis, J. Moreau, 1998, AIDS.

CD4+ lymphocyte count and plasma HIV RNA levels in a survey of 1602 HIV-infected patients in Bordeaux, France, 1996-1997. Groupe d'Epidemiologie Clinique da SIDA en Aquitaine.

D. Neau, J. Moreau, D. Malvy, 1998, AIDS (London).